Vemurafenib is a BRAF inhibitor approved by the United States in FDA2011. It is mainly used for the treatment of advanced melanoma. Clinical studies have shown that the drug resistance of Verofenib is more prominent, and the condition is relieved in the first few months of application. However, in most cases, melanoma recurs in the following months. Therefore, it is gradually necessary to find verafenib sensitizers. Researchers in the industry have paid attention to the efficacy of verafenib. Some studies have found that phenformin has a sensitizing effect on verafenib. As a verafenib sensitizer; there are studies looking for verafenib sensitizer from natural drugs. The only Ro Fini intermediate is 2, 6-difluoro-3-(propylsulfonamide) benzoic acid, which is mainly used to synthesize Ro Fini